Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Athena Bioscience's New Drug Application (NDA) for QDOLO\u2122 (tramadol hydrochloride) Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma, Athena Bioscience Enter Exclusive License Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Sabal Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sabal Therapeutics Announces Sales and Marketing Agreement to Promote Athena Bioscience Cardiovascular Product Portfolio","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athena Bioscience Announces Launch of Nexiclon\u2122 XR, the Only Once-Daily Clonidine Extended-Release Tablets for Treatment of Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Athena Bioscience

    Menu

    Athena Bioscience

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Athena Bioscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Release Tablets for Treatment of Hypertension

              Details:

              The launch of Nexiclon XR, the only once-daily clonidine extended-release tablets is based on Tris's LiquiXR drug delivery technology, which has led to the development of multiple first-in-category products indicated for treatment of hypertension.

              Lead Product(s): Clonidine

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexiclon

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Athena Bioscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sabal Therapeutics Announces Sales and Marketing Agreement to Promote Athena Bioscience Cardiovascular Product Portfolio

              Details:

              This partnership aligns perfectly with Sabal’s mission to support commercial launch for two products, Nexiclon™ XR and Fibricor®, by helping them deliver their products to physicians and patients who need them.

              Lead Product(s): Clonidine

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexiclon XR

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Sabal Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Athena Bioscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tris Pharma, Athena Bioscience Enter Exclusive License Agreement

              Details:

              The licensed product upon launch, will be the only once-daily formulation containing an established Active Pharmaceutical Ingredient (API), which physicians can optionally prescribe alone or concomitantly with other antihypertensive agents to pursue desired outcomes.

              Lead Product(s): Undisclosed

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Tris Pharma Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Athena Bioscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              U.S. FDA Approves Athena Bioscience's New Drug Application (NDA) for QDOLO™ (tramadol hydrochloride) Oral Solution

              Details:

              USFDA has approved QDOLO™ (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

              Lead Product(s): Tramadol Hydrochloride

              Therapeutic Area: Neurology Product Name: Qdolo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY